Author:
Juif Pierre-Eric,Boehler Margaux,Donazzolo Yves,Bruderer Shirin,Dingemanse Jasper
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference34 articles.
1. Actelion Pharmaceuticals US Inc. US prescribing information: Uptravi (selexipag) tablets, for oral use (2015). vol Available from:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207947s000lbl.pdf
.
2. Scott LJ (2016) Selexipag: first global approval. Drugs 76(3):413–418. doi:
10.1007/s40265-016-0549-4
3. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV, Investigators G (2015) Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 373(26):2522–2533. doi:
10.1056/NEJMoa1503184
4. Actelion Pharmaceuticals Ltd. Uptravi: EU summary of product characteristics. (2016).
http://www.ema.europa.eu
. Accessed 8 Nov 2016
5. Kaufmann P, Niglis S, Bruderer S, Segrestaa J, Aanismaa P, Halabi A, Dingemanse J (2015) Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjects. Br J Clin Pharmacol 80(4):670–677. doi:
10.1111/bcp.12650
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献